On August 1st, Liu Liyang, President of Nanjing University Science and Technology Innovation Investment Alumni Association, and Wang Wei, Vice President, and their delegation came to visit for investigation and guidance. Our founder Li Shiyan and co-founder Liu Mingming, Chairman of Nanjing Innovation Research Institute Jiang Xiaozhong, Strategic Investment Department Zhang Zengqi and others jointly received him.
Li Shiyan, the founder of Jinran Biotechnology, first extended a warm welcome to the arrival of Liu Liyang and President Wang Wei, and introduced the project situation in detail through exchanges and discussions from the broad product industry development prospects to the R&D team, technical advantages, business models and other aspects. .
During the exchange and discussion, the two presidents, Liu Liyang and Wang Wei, highly recognized the project status of our company.Chairman Wang Wei focused on asking about the company's current major customers, market sales models and competitive advantages, and provided numerous guidance from the perspective of entrepreneurial survival; Chairman Liu Liyang focused on the actual application scenarios and future market capacity of the company's various products. , and make targeted and pertinent suggestions.Li Shiyan and Liu Mingming, the founders of Jinran Biotechnology Company, conducted exchanges and discussions with the two presidents respectively on these issues concerning the development of the enterprise.
This visit and exchange event ended successfully with everyone’s heated discussion. Jin Ran is very grateful to the NTU Science and Technology Innovation Investment Alumni Association for its recognition, guidance and care!
★Introduction to Jinran Biotechnology★
As an enterprise introduced by Nanchuang Research Institute, Jinran Biotechnology was established inIn June 2020, it is a company integrating R&D, production and sales.Green and intelligent manufacturing enterprise of high-quality chiral compounds and materials.The company relies on the founding team's more than ten years of R&D and industrialization experience in synthetic biology and is committed to the design, R&D, production and sales of new bio-based molecules and materials.At present, the company has developed a number of platform technologies such as biological fermentation technology, enzyme big data analysis and directed evolution technology, green catalytic chiral compound screening and amplification technology, and degradable material polymerization and performance testing platforms.
Based on the company's technology platform, Jinran Biotechnology now has multiple product pipelines, including high-end cosmetic active substances, new health food additives, chiral pharmaceutical intermediates, unnatural amino acids, degradable and environmentally friendly materials, etc., and is committed to assisting through biosynthesis Human beings realize their desire to create a better life!
Post time: Aug-02-2023